Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael T Schweizer

Showing results (1-10 of 119) with videos related to

Pageof 12
Sort By:
Medical Oncology (Northwood, London, England)|April 5, 2016
Targeting persistent androgen receptor signaling in castration-resistant prostate cancerLaura Graham, Michael T Schweizer
Expert Opinion on Therapeutic Targets|August 6, 2016
Response: letter to the editorMichael T Schweizer, Stephen R Plymate
Science Translational Medicine|November 6, 2015
Liquid biopsy: Clues on prostate cancer drug resistanceMichael T Schweizer, Emmanuel S Antonarakis
Cancer Journal (Sudbury, Mass.)|January 23, 2013
From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancerMichael T Schweizer, Michael A Carducci
The Prostate|March 31, 2022
Mismatch repair deficiency and clinical implications in prostate cancerLaura S Graham, Michael T Schweizer
The Lancet. Oncology|November 13, 2012
Abiraterone acetate: a hat trick of clinical benefitsMichael T Schweizer, Emmanuel S Antonarakis
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2020
"Matching" the "Mismatch" Repair-Deficient Prostate Cancer with ImmunotherapyMichael T Schweizer, Evan Y Yu
Therapeutic Advances in Medical Oncology|September 2, 2016
Targeting intratumoral androgens: statins and beyondMichael T Schweizer, Evan Y Yu
Clinical Genitourinary Cancer|May 4, 2017
Durable Response to Immune Checkpoint Blockade in a Platinum-Refractory Patient With Nonseminomatous Germ Cell TumorEthan A Chi, Michael T Schweizer
Cancers|January 14, 2017
AR-Signaling in Human Malignancies: Prostate Cancer and BeyondMichael T Schweizer, Evan Y Yu
Pageof 12

Showing results (1-10 of 119) with videos related to

Sort By:
Pageof 12
Medical Oncology (Northwood, London, England)|April 5, 2016
Targeting persistent androgen receptor signaling in castration-resistant prostate cancerLaura Graham, Michael T Schweizer
Expert Opinion on Therapeutic Targets|August 6, 2016
Response: letter to the editorMichael T Schweizer, Stephen R Plymate
Science Translational Medicine|November 6, 2015
Liquid biopsy: Clues on prostate cancer drug resistanceMichael T Schweizer, Emmanuel S Antonarakis
Cancer Journal (Sudbury, Mass.)|January 23, 2013
From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancerMichael T Schweizer, Michael A Carducci
The Prostate|March 31, 2022
Mismatch repair deficiency and clinical implications in prostate cancerLaura S Graham, Michael T Schweizer
The Lancet. Oncology|November 13, 2012
Abiraterone acetate: a hat trick of clinical benefitsMichael T Schweizer, Emmanuel S Antonarakis
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2020
"Matching" the "Mismatch" Repair-Deficient Prostate Cancer with ImmunotherapyMichael T Schweizer, Evan Y Yu
Therapeutic Advances in Medical Oncology|September 2, 2016
Targeting intratumoral androgens: statins and beyondMichael T Schweizer, Evan Y Yu
Clinical Genitourinary Cancer|May 4, 2017
Durable Response to Immune Checkpoint Blockade in a Platinum-Refractory Patient With Nonseminomatous Germ Cell TumorEthan A Chi, Michael T Schweizer
Cancers|January 14, 2017
AR-Signaling in Human Malignancies: Prostate Cancer and BeyondMichael T Schweizer, Evan Y Yu
Pageof 12